Literature DB >> 17468402

Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.

Beverly W Baron1, Nancy Zeleznik-Le, Miriam J Baron, Catherine Theisler, Dezheng Huo, Matthew D Krasowski, Michael J Thirman, Rebecca M Baron, Joseph M Baron.   

Abstract

The human BCL6 gene on chromosome 3 band q27, which encodes a transcriptional repressor, is implicated in the pathogenesis of human lymphomas, especially the diffuse large B-cell type. We previously identified the human PDCD2 (programmed cell death-2) gene as a target of BCL6 repression. PDCD2 encodes a protein that is expressed in many human tissues, including lymphocytes, and is known to interact with corepressor complexes. We now show that BCL6 can bind directly to the PDCD2 promoter, repressing its transcription. Knockdown of endogenous BCL6 in a human B cell lymphoma line by introduction of small interfering RNA duplexes increases PDCD2 protein expression. Furthermore, there is an inverse relationship between the expression levels of the BCL6 and PDCD2 proteins in the lymphoid tissues of mice overexpressing human BCL6 (high BCL6 levels, minimal PDCD2) and controls (minimal BCL6, high PDCD2) as well as in tissues examined from some human B and T cell lymphomas. These data confirm PDCD2 as a target of BCL6 and support the concept that repression of PDCD2 by BCL6 is likely important in the pathogenesis of certain human lymphomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17468402      PMCID: PMC1863460          DOI: 10.1073/pnas.0701770104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.

Authors:  C C Chang; B H Ye; R S Chaganti; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.

Authors:  C W Wong; M L Privalsky
Journal:  J Biol Chem       Date:  1998-10-16       Impact factor: 5.157

3.  Transcriptional repression by the proto-oncogene BCL-6.

Authors:  V L Seyfert; D Allman; Y He; L M Staudt
Journal:  Oncogene       Date:  1996-06-06       Impact factor: 9.867

4.  BCL-6 expression during B-cell activation.

Authors:  D Allman; A Jain; A Dent; R R Maile; T Selvaggi; M R Kehry; L M Staudt
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

5.  6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas.

Authors:  M Merup; T C Moreno; M Heyman; K Rönnberg; D Grandér; R Detlofsson; O Rasool; Y Liu; S Söderhäll; G Juliusson; G Gahrton; S Einhorn
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

6.  BCL6 can repress transcription from the human immunodeficiency virus type I promoter/enhancer region.

Authors:  B W Baron; M Desai; L J Baber; L Paras; Q Zhang; A Sadhu; S Duguay; G Nucifora; T W McKeithan; N Zeleznik-Le
Journal:  Genes Chromosomes Cancer       Date:  1997-05       Impact factor: 5.006

7.  The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.

Authors:  C Deweindt; O Albagli; F Bernardin; P Dhordain; S Quief; D Lantoine; J P Kerckaert; D Leprince
Journal:  Cell Growth Differ       Date:  1995-12

8.  Cloning of mouse RP-8 cDNA and its expression during apoptosis of lymphoid and myeloid cells.

Authors:  D L Vaux; G Häcker
Journal:  DNA Cell Biol       Date:  1995-03       Impact factor: 3.311

9.  BCL6 encodes a sequence-specific DNA-binding protein.

Authors:  B W Baron; R R Stanger; E Hume; A Sadhu; R Mick; J P Kerckaert; C Deweindt; C Bastard; G Nucifora; N Zeleznik-Le
Journal:  Genes Chromosomes Cancer       Date:  1995-07       Impact factor: 5.006

10.  Recognition DNA sequence of a novel putative transcription factor, BCL6.

Authors:  N Kawamata; T Miki; K Ohashi; K Suzuki; T Fukuda; S Hirosawa; N Aoki
Journal:  Biochem Biophys Res Commun       Date:  1994-10-14       Impact factor: 3.575

View more
  19 in total

1.  Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4.

Authors:  Verena Schuette; Maria Embgenbroich; Thomas Ulas; Meike Welz; Jonas Schulte-Schrepping; Astrid M Draffehn; Thomas Quast; Katharina Koch; Melanie Nehring; Jessica König; Annegret Zweynert; Frederike L Harms; Nancy Steiner; Andreas Limmer; Irmgard Förster; Friederike Berberich-Siebelt; Percy A Knolle; Dirk Wohlleber; Waldemar Kolanus; Marc Beyer; Joachim L Schultze; Sven Burgdorf
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

2.  PDCD2 is essential for inner cell mass development and embryonic stem cell maintenance.

Authors:  Weipeng Mu; Robert J Munroe; Anna K Barker; John C Schimenti
Journal:  Dev Biol       Date:  2010-09-09       Impact factor: 3.582

3.  The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.

Authors:  Beverly W Baron; Rebecca M Baron; Joseph M Baron
Journal:  Biochim Biophys Acta       Date:  2014-12-31

4.  Computational and functional analysis of growth hormone (GH)-regulated genes identifies the transcriptional repressor B-cell lymphoma 6 (Bc16) as a participant in GH-regulated transcription.

Authors:  Yili Chen; Grace Lin; Jeffrey S Huo; Deborah Barney; Zhenni Wang; Tamara Livshiz; David J States; Zhaohui S Qin; Jessica Schwartz
Journal:  Endocrinology       Date:  2009-04-30       Impact factor: 4.736

5.  PDCD2 knockdown inhibits erythroid but not megakaryocytic lineage differentiation of human hematopoietic stem/progenitor cells.

Authors:  Natalia A Kokorina; Celine J Granier; Stanislav O Zakharkin; Stephani Davis; Arnold B Rabson; Hatem E Sabaawy
Journal:  Exp Hematol       Date:  2012-08-22       Impact factor: 3.084

6.  NORE1A tumor suppressor candidate modulates p21CIP1 via p53.

Authors:  Diego F Calvisi; Howard Donninger; Michele D Vos; Michael J Birrer; Laura Gordon; Virna Leaner; Geoffrey J Clark
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

7.  PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia.

Authors:  Nora Barboza; Svetlana Minakhina; Daniel J Medina; Binaifer Balsara; Sonya Greenwood; Lien Huzzy; Arnold B Rabson; Ruth Steward; Dale G Schaar
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

8.  Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1.

Authors:  Won-Il Choi; Bu-Nam Jeon; Chae-Ok Yun; Pyung-Hwan Kim; Sung-Eun Kim; Kang-Yell Choi; Se Hoon Kim; Man-Wook Hur
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

9.  PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors.

Authors:  Wei Wang; Xiao-Wen Song; Xian-Min Bu; Ning Zhang; Cheng-Hai Zhao
Journal:  Cell Oncol (Dordr)       Date:  2015-11-20       Impact factor: 6.730

10.  Repression of miR-31 by BCL6 stabilizes the helper function of human follicular helper T cells.

Authors:  A Ripamonti; E Provasi; M Lorenzo; M De Simone; V Ranzani; S Vangelisti; S Curti; R J P Bonnal; L Pignataro; S Torretta; J Geginat; G Rossetti; M Pagani; S Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.